First Course of Treatment and Prognosis of Exocrine Pancreatic Cancer in Korea from 2006 to 2017

Mee Joo Kang1,2, Jiwon Lim2, Sung-Sik Han1, Hyeong Min Park1, Sang-Jae Park1, Young-Joo Won2,3, Sun-Whe Kim1

1Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, 2Division of Cancer Registration and Surveillance, National Cancer Center, Goyang, 3Department of Cancer Control & Population Health, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea

Purpose Hospital-based clinical studies have limitations in holistic assessment of cancer treatment and prognosis, as they omit out-of-hospital patients including elderly individuals. This study aimed to investigate trends in initial treatment and corresponding prognosis of patients with exocrine pancreatic cancer (EPC) in Korea.

Materials and Methods The Korea Central Cancer Registry data of patients with EPC from 2006 to 2017 were retrospectively reviewed. We defined the first course of treatment (FT) as the cancer-directed treatment administered within four months after cancer diagnosis according to the Surveillance, Epidemiology, and End Results (SEER) program.

Results Among 62,209 patients with EPC, localized and regional (LR) SEER stage; patients over 70 years old; and ductal adenocarcinoma excluding cystic or mucinous (DAC) accounted for 40.6%, 50.1%, and 95.9%, respectively. “No active treatment” (NT, 46.5%) was the most frequent, followed by non-surgical FT (28.7%) and surgical FT (22.0%). Among 25,198 patients with LR EPC, surgical FT increased (35.9% to 46.3%) and NT decreased (45.0% to 29.5%) from 2006 to 2017. The rate of surgical FT was inversely related to age (55.1% [< 70 years], 37.3% [70-79 years], 10.9% [≥ 80 years]). Five-year relative survival rates of LR DAC were higher after surgical FT than after NT in localized (46.1% vs. 12.9%) and regional stage (23.6% vs. 4.9%) from 2012 to 2017.

Conclusion Less than half of overall patients with LR EPC underwent surgical FT, and this proportion decreased significantly in elderly individuals. Clinicians should focus attention on elderly patients with EPC to provide appropriate medical advice.

Key words Pancreatic neoplasms, Therapeutics, Survival rate, Registries

Introduction

Despite recent advances in diagnostic modalities, surgical care, medical oncology, and radiation oncology, pancreatic cancer remains the seventh leading cause of global cancer deaths with limited improvements in survival outcomes [1]. However, clinical studies have limitations in holistic assessment of patients who do not present to hospitals for cancer-directed treatments. Little is known, nationally, about the treatment pattern including temporal trends and age-related disparities in many countries.

During the past decades, authoritative guidelines including those from the National Comprehensive Cancer Network (NCCN) [2], American Society of Clinical Oncology (ASCO) [3], European Society for Medical Oncology (ESMO) [4], and other academic societies were globally adopted for pancreatic cancer treatment. Nevertheless, only 48.4% of patients with pancreatic cancer received the nationally expected treatment, while 36.9% did not receive any treatment in the United States from 2004 to 2013 [5]. A recent population-based study in Europe and the United States also revealed wide variations in the proportion of patients receiving chemotherapy (12.5%-61.7%) or radiation therapy (22.6%-32.6%) after resection of pancreatic cancer [6].

However, the life expectancy at birth in countries with an age-standardized incidence rate of pancreatic cancer higher than 7.0 per 100,000 is 81.0 years [1,7], when the median age at diagnosis of pancreatic cancer is 70 years [8]. However, few studies have focused on the disparities in treatment pattern according to the patients’ age. In the United States, from 2004 to 2011, patients with stages I and II pancreatic adenocarcinoma in the age groups 56-64, 65-75, and 76 years or older were 17%, 40%, and 83% less likely to undergo surgery and receive chemotherapy in combination, either as adjuvant or neoadjuvant treatment, compared to those aged 18-55 years [9]. From 2011 to 2016, 52% of patients in their 80s with local-
ized pancreatic head ductal adenocarcinoma did not receive any cancer-directed treatment in the United States [10]. Therefore, identifying the treatment pattern for an entire nation may provide a better insight into cancer management in the population, especially taking into consideration those that are under-represented in hospital-based clinical studies. In this study, trends in initial treatment pattern and corresponding prognosis of exocrine pancreatic cancer (EPC) were investigated using a nationally representative population-based cancer registry data in Korea from 2006 to 2017.

Materials and Methods

1. Data source

Epidemiologic data were obtained from the Korea Central Cancer Registry (KCCR), which has annually collected incidence data from the entire Korean population in all regions since 1999 [11]. In KCCR, the Surveillance, Epidemiology, and End Results (SEER) stage has been formally recorded since 2006 as localized (a malignancy limited to the organ of origin), regional (tumor extension beyond the limits of organ of origin), distant (a tumor that has spread to areas of the body distant from the primary tumor), and unknown (sufficient evidence is not available to adequately assign stage) tumors [12]. Therefore, this study analyzed data from 2006 to 2017 to stratify treatment pattern and prognosis in relation to the SEER stage.

2. Patient cohort

This study focused on EPC, as distinct from that of pancreatic neuroendocrine tumors, which have relatively higher survival rates compared to EPC [13]. Of the 64,308 individuals with pancreatic cancer coded as C25 according to the International Classification of Diseases, 10th revision (ICD-10) [14], 2,099 individuals with the following morphology codes for neuroendocrine tumors were excluded: 8150-8157, 8240-8246, 8249, 8002, 8040-8045, and 8013 [15]. The morphology codes for EPC were used to categorize individuals into three mutually exclusive groups: ductal adenocarcinoma excluding cystic or mucinous (DAC; 8000-8004, 8010-8011, 8020-8039, 8230-8231, 8140-8149, 8490, 8500-8503, 8560-8570), ductal specified as mucinous or cystic adenocarcinoma (ADC, 8050-8260, 8440-8479, 8480-8481), and acinar cell carcinoma (ACC; 8550) [16]. Consequently, 62,209 patients with EPC were included in this study, and their demographic characteristics, overall yearly treatment pattern, and survival outcomes were examined. Then, 10,045 patients with missing SEER stage or treatment information were excluded at subgroup analysis regarding treatment pattern related to the SEER stage.

3. First course of treatment

In the registry, the “first course of treatment” (FT) was recorded based on the documented cancer-directed treatment methods used to administer treatment to the patients before disease progression or recurrence, within the first four months of the date of initial diagnosis [12,17]. Nine categories of treatment information were included in the registry: surgery alone, surgery with chemotherapy, surgery with radiotherapy, surgery with chemotherapy and radiotherapy, chemotherapy alone, chemotherapy with radiotherapy, radiotherapy alone, no active treatment, and unknown treatment information. In this study, the treatment pattern was aggregated into four groups: surgical FT (surgery alone, surgery with chemotherapy, surgery with radiotherapy, surgery with chemotherapy and radiotherapy); non-surgical FT (chemotherapy alone, chemotherapy with radiotherapy, radiotherapy alone); no active treatment (NT); and unknown.

4. Statistical analysis

The study period was divided into periods I (2006-2011) and II (2012-2017). Age was stratified into < 40, 40-49, 50-59, 60-69, 70-79, and ≥ 80 years, then aggregated into four groups (< 60, 60-69, 70-79, and ≥ 80 years) for the statistical tests. Owing to the inability to differentiate the American Joint Committee on Cancer (AJCC) stage or resectability based on the SEER stage, as recorded in the registry, localized and regional stages were considered as a whole to analyze the treatment pattern, which may have included resectable, borderline resectable, and locally advanced unresectable tumors. The categorical variables were compared using the chi-square test. Adjusted risk ratios were analyzed using binreg command in STATA ver. 16.1 (StataCorp LLC, College Station, TX). Relative survival rates were estimated using the Ederer II method with some minor modifications, based on an algorithm written in SAS provided by Paul Dickman [18]. Analyses of survival were performed using SAS ver. 9.4 (SAS Institute Inc., Cary, NC). All statistical tests were two-tailed, and results were considered statistically significant at p-values < 0.05.

Results

1. Overall epidemiology, treatment pattern, and prognosis of patients with EPC

Among the 62,209 patients with EPC, 50.1% were aged 70 years or older (Table 1). The proportion of patients aged 70 years or older increased from 47.0% (period I) to 52.3% (period II). Comparing periods I and II, the proportion of regional and distant SEER stage increased while localized and unknown stage decreased.
The proportion of unknown SEER stage was higher in elderly patients (11.5% [< 60 years, n=1,656] vs. 11.9% [60-69 years, n=1,988] vs. 16.2% [70-79 years, n=3,309] vs. 28.6% [≥ 80 years, n=3,051], p < 0.001). Among patients with available information on SEER stage, the proportion of localized and regional stage was comparable across age groups (48.1% [< 60 years, n=6,142] vs. 48.5% [60-69 years, n=7,120] vs. 48.2% [70-79 years, n=8,281] vs. 48.5% [≥ 80 years, n=3,685], p=0.896).

Of all SEER stages, the proportion of patients receiving surgical FT and non-surgical FT increased while those with NT decreased (Fig. 1A). Among patients with localized and regional stage EPC with available information on treatment (n=25,198), the proportion of patients receiving surgical FT (39.3% to 45.2%) and non-surgical FT (19.9% to 20.7%) increased while those with NT decreased (40.8% to 34.1%). In distant-stage EPC with available information on treatment (n=26,966), the proportion of non-surgical FT increased (36.4% to 43.2%), and those with NT (54.9% to 48.5%) and surgical FT (8.7% to 8.3%) decreased.

From period I to II, the overall 5-year relative survival rate (5YRS) significantly increased in all stages (8.0% [period I] to 9.8% [period II], p < 0.001), localized stage (21.6% to 28.1%, p=0.035), and regional stage (11.2% to 15.3%, p < 0.001) (Fig. 1B).

Comparing among the three histology groups, patients with DAC had higher proportion of patients aged 70 years or older (50.9% [n=30,383] vs. 30.7% [n=718], p < 0.001), with a
lower percentage of surgical FT (20.1% [n=11,981] vs. 69.0% [n=1,613], p < 0.001) and localized and regional SEER stage (39.4% [n=23,508] vs. 69.3% [n=1,621], p < 0.001) compared to those with ADCm&c. The proportion of patients receiving surgical FT was higher in younger patients, males, and patients with ADCm&c and ACC histology (Table 2). After adjusting for period, sex, and histology groups, patients in their 70s and 80s or older had a 29.7% and 79.3% reduced incidence of surgical FT compared to those under the age of 60 years (Table 3).

2. Changes in the treatment pattern and prognosis of patients with ductal adenocarcinoma

Among 59,685 patients with DAC, 39.4% had localized and regional stage and 44.2% had distant SEER stage. Among 23,481 patients with localized and regional stage DAC with available information on treatment, the proportion of patients undergoing surgical FT increased from period I to II (Fig. 2A), for both localized (21.6% [n=513] to 23.0% [n=674]) and regional (41.3% [n=3,003] to 46.8% [n=5,106]) stages.

Patients’ age was inversely related to the proportion of surgical FT. The proportion of patients receiving surgical FT in patients aged < 60 years, 60-69 years, 70-79 years, and ≥ 80 years were 52.4%, 44.2%, 29.1%, and 5.6%, respectively, in period I and 55.5%, 53.6%, 38.8%, and 12.1%, respectively, in period II. On the contrary, the proportion of patients with NT was the highest in patients aged ≥ 80 years (87.1% [period I] to 79.7% [period II]) (Fig. 2B).

Among 26,359 patients with distant stage DAC and information available on treatment, the proportion of patients undergoing non-surgical FT increased from period I to II (36.3% to 55.3%) while the proportion of patients with NT decreased (55.3% to 48.9%) (Fig. 2C).

The overall 5YRS of DAC increased from 6.8% to 7.9%
(15.7% to 18.2% [localized], 9.9% to 13.4% [regional], and 1.5% to 1.6% [distant SEER stage]) (Fig. 2D). Prognosis after surgical FT was better than that after non-surgical FT or NT in patients with localized and regional stage DAC. A higher 5YRS in the NT group than in the non-surgical FT group was due to the lower microscopic verification rate (26.7% [761/2,845] vs. 71.8% [610/850]), respectively.

3. Epidemiology, treatment pattern, and prognosis of patients with mucinous and cystic adenocarcinomas

Among 2,338 patients with ADCm&c, 30.7% were aged over 70 years and the male-to-female ratio was 1.03:1. At the time of diagnosis, 69.3% had localized or regional disease, and 22.8% had distant SEER stage disease. Proportion of patients receiving surgical FT among 1,618 patients with localized and regional stage ADCm&c increased from 82.8% (period I,

Table 2. Characteristics of patients according to first course of treatment in localized and regional stage exocrine pancreatic cancer

| Variable                        | No.          | Surgical FT (n=10,781) | Non-surgical FT (n=5,134) | NT (n=9,283) | p-valuea |
|---------------------------------|--------------|------------------------|---------------------------|--------------|----------|
| Age at diagnosis (yr)           |              |                        |                           |              |          |
| 0-59                            | 13,241       | 3,588 (58.5)           | 1,592 (26.0)              | 953 (15.5)   | < 0.001  |
| 60-69                           | 7,108        | 3,707 (52.2)           | 1,760 (24.8)              | 1,641 (23.1) |          |
| 70-79                           | 8,272        | 3,084 (37.3)           | 1,491 (18.0)              | 3,697 (44.7) |          |
| ≥ 80                            | 3,685        | 402 (10.9)             | 291 (7.9)                 | 2,992 (81.2) |          |
| Sex                             |              |                        |                           |              |          |
| Male                            | 13,324       | 6,098 (45.8)           | 2,869 (21.5)              | 4,357 (32.7) | < 0.001  |
| Female                          | 11,874       | 4,683 (39.4)           | 2,265 (19.1)              | 4,926 (41.5) |          |
| Histology                       |              |                        |                           |              |          |
| Ductal adenocarcinoma excluding cystic or mucinous (DAC) | 23,481       | 9,296 (39.6)           | 5,035 (21.4)              | 9,150 (39.0) | < 0.001  |
| Ductal specified as mucinous or cystic adenocarcinoma (ADCm&c) | 1,618        | 1,403 (86.7)           | 91 (5.6)                  | 124 (7.7)    |          |
| Acinar cell carcinoma (ACC)     | 99           | 82 (82.8)              | 8 (8.1)                   | 9 (9.1)      |          |

Values are presented as number (%). FT, first course of treatment; NT, no active treatment. aChi-square test across three types of treatment pattern.

Table 3. Risk ratio of receiving surgical treatment within 4 months after diagnosis of localized and regional stage exocrine pancreatic cancer, adjusted for time period, age at diagnosis, sex, and histology

| Year        | Risk ratio | 95% CI     | p-value |
|-------------|------------|------------|---------|
| 2006-2011   | 1          |            |         |
| 2012-2017   | 1.141      | 1.112-1.170| < 0.001 |
| Age (yr)    |            |            |         |
| < 60        | 1          |            |         |
| 60-69       | 0.956      | 0.932-0.980| < 0.001 |
| 70-79       | 0.703      | 0.680-0.727| < 0.001 |
| ≥ 80        | 0.207      | 0.189-0.228| < 0.001 |
| Sex         |            |            |         |
| Male        | 0.990      | 0.969-1.012| 0.371   |
| Female      |            |            |         |
| Histology   |            |            |         |
| Ductal adenocarcinoma excluding cystic or mucinous (DAC) | 1.749      | 1.707-1.792| < 0.001 |
| Ductal specified as mucinous or cystic adenocarcinoma (ADCm&c) | 1.662      | 1.516-1.823| < 0.001 |

CI, confidence interval.
Fig. 2. Treatment pattern and prognosis of patients with ductal adenocarcinoma. (A) Yearly cases and treatment pattern in localized and regional Surveillance, Epidemiology, and End Results (SEER) stage. (B) Proportion of patients receiving surgical first course of treatment and no active treatment according to age group in localized and regional SEER stage. (C) Yearly cases and treatment pattern in distant SEER stage. (Continued to the next page)
n=468) to 88.9% (period II, n=917) (Fig. 3A). The overall 5YRS of ADC increased from 40.3% to 56.5%, with more marked improvement in patients with localized (73.4% to 86.4%, p < 0.001) and regional (38.1% to 55.5%, p < 0.001) disease (Fig. 3B).

4. Epidemiology, treatment pattern, and prognosis of patients with ACC

Among 186 patients with ACC, 21.5% were aged over 70 years and the male-to-female ratio was 2.32:1. At the time of diagnosis, 53.2% had localized or regional disease, and 40.3% had distant SEER stage disease. The data of ACC were not analyzed according to periods owing to the small sample size in each stratum. Overall, 53.8% had surgical FT, 24.7% had non-surgical FT, and 21.0% had NT. The overall 5YRS of ACC from 2006 to 2017 was 29.7%, which was higher after surgical FT than with NT (44.7% and 12.2%, respectively).

Discussion

Medical, financial, logistical, psychosocial, and several other barriers can prevent a patient from receiving optimal cancer treatment [19]. Geographical disparities in treatment pattern owing to limited access to specialized consultation have been reported in the United States [20] and Canada [21,22]. However, South Korea is privileged to have the National Health Insurance that has covered the entire nation since 1989 in addition to a well-established one-day life zone across the country [23]. Consequently, patients with cancer in Korea can receive optimal treatment by visiting specialized high-volume centers with minimal delay in a nearly homogenous manner [24]. Therefore, the treatment pattern of pancreatic cancer in Korea may serve as a good proxy of population-based data with minimal barriers in geographical distribution and inefficiencies in logistics or health care delivery systems.

Based on the Korean national data, in this study, the proportion of patients with localized and regional stage EPC undergoing surgical FT increased from 39.3% (period I) to 45.2% (period II). The results are comparable to those reported in the United States, where the proportion increased from 29.6% (stage I, 1995-2004) [25] to 41.1% (stage I-II, 2004-2013) [5]. Although the SEER stage used in this study could not differentiate between patients with resectable, borderline resectable, or locally advanced disease, patients who underwent surgical FT for localized or regional stage EPC had better survival outcomes compared to those with non-surgical FT and NT. This was concordant with a previous study that revealed better prognosis in patients with stage III EPC who underwent unexpected surgical FT compared to those who received NT [10]. In this study, treatment modalities administered later than four months after diagnosis were not recorded; therefore, those who received neoadjuvant treatment with surgery could have been classified as non-surgical FT. Moreover, time to treatment in pancreatic cancer was not considered to be related to poor prognosis [26]. However, our data revealed a prognostic benefit in those who began cancer-directed treatment within the first four months after the diagnosis of pancreatic cancer.

Among the elderly individuals with localized and regional stage EPC, 44.2% of those aged between 60 and 79 years in
Korea underwent surgical FT, which is comparable to that in the United States (46.7%, 2011-2016) [10]. However, this study revealed that the adjusted risk of undergoing surgical FT in septuagenarians was 28.0% lower than that for patients under the age of 70 years. Moreover, 10.9% of octogenarians or older with localized or regional EPC in Korea underwent surgical FT with an adjusted risk of undergoing surgical FT that was 78.8% lower than that for patients under the age of 70 years. The proportion of Korean octogenarians undergoing surgical FT for localized and regional EPC was higher than that in the Netherlands (5.5%, 2005-2013) [27] or Japan (less than 10%, 2010-2018) [28], but lower than that in the United States (20.9%, 2011-2016) [10]. Although this study did not identify treatment modalities administered more than four months after the diagnosis of EPC, it has been reported that elderly individuals were less likely to undergo chemotherapy or radiation therapy in combination with surgery [5,6,9]. The fact that elderly individuals undergo fewer cancer-directed treatments emphasizes the importance of taking this group more actively into consideration, especially those in their 70s who are no longer considered as being “too old” to receive surgical or non-surgical anticancer treatment. Owing to non-oncologic comorbidities and declining physiological function in elderly individuals, there are still debates on finding a balance between surgical morbidity, mortality, and survival benefit in elderly individuals. Previous studies revealed that elderly individuals tended to “not be offered surgery” [25], even after adjusting for their comorbidities.
Moreover, elderly individuals have been under-represented in clinical trials for cancer treatment. Therefore, objective criteria to screen and select elderly patients for appropriate cancer-directed treatment tailored to this age group should be developed in collaboration with gerontologists [29].

This study has several limitations. First, the cancer registry did not capture information on treatment that was administered later than the first 4 months after the diagnosis of EPC. Therefore, the exact proportion of patients receiving multimodality treatment could not be evaluated in this study. However, the Korea National Health Insurance Claim data that has no limitation of timing or sequence of treatment revealed less than 2% of patients received surgical treatment after the first 4 months (unpublished data). Consequently, we assume that the proportion of surgical FT approaches the real-world data, while NT could have been underestimated in this study. Second, treatment information recorded in the registry was insufficient regarding the name of the operation and the regimen and duration of chemotherapy or radiation therapy. Hence, surgical FT did not mandate a pancreaticoduodenectomy but could have included palliative surgeries. In addition, reasons for not receiving treatment within the first four months could not be identified in this study. Therefore, future studies utilizing National Health Insurance Claim data in combination with the cancer registry database should be conducted to investigate treatment patterns in detail throughout the entire follow-up period of patients with pancreatic cancer. Third, the SEER stage has limited clinical implications in relation to identifying the AJCC stage or applying the concept of resectability for pancreatic cancer. Therefore, future studies should incorporate information on comprehensive staging and evidence used for the clinical staging in the cancer registries. Lastly, the category of ADCm&c could have been underestimated in its number compared to clinical entity because it was classified based only on the morphology codes, without any information on the radiological features.

In addition, there was a risk of overestimating the proportion of patients receiving surgical FT and the prognosis of EPC underwent surgical FT. The proportion of those that receiving surgical FT was inversely related to the patients’ age; thus, 37.3% of septuagenarians and 10.9% of octogenarians or older underwent surgical FT. Those who underwent surgical FT had a better prognosis compared to those with non-surgical FT or NT, regardless of histology groups. Pancreatic cancer treatment guidelines need to be tailored to elderly individuals, whose proportions are increasing as life expectancy increases globally. Future clinical studies should be more inclusive of elderly individuals to establish evidence that can support the treatment guidelines for this age group.

**Ethical Statement**

The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the human research committee of the National Cancer Center, with an exemption of written informed consent because of the retrospective study design (IRB No. NCC2020-0334).

**Author Contributions**

Conceived and designed the analysis: Kang MJ, Won YJ, Kim SW. Collected the data: Lim J. Performed the analysis: Lim J, Kang MJ, Won YJ, Kim SW. Drafting the article, critical revision, and final approval: Kang MJ, Lim J, Han SS, Park HM, Park SJ, Kim SW, Won YJ.

**Conflicts of Interest**

Conflict of interest relevant to this article was not reported.

**Acknowledgments**

This work was supported by a research grant (No. 1910132-3) from the National Cancer Center, Republic of Korea.

**References**

1. The Global Cancer Observatory. Cancer today; pancreas (C25) [Internet]. Lyon: International Agency for Research on Cancer; c2020 [cited 2021 Mar 5]. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/13-Pancreas-fact-sheet.pdf.
2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma, version 2.2021 [Internet]. Plymouth Meeting, PA: National Comprehensive Cancer Network; c2021 [cited 2021 Mar 5]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.
3. Khorana AA, McKernin SE, Berlin J, Hong TS, Maitra A, Moravek C, et al. Potentially curable pancreatic adenocarcin-
nom: ASCO clinical practice guideline update. J Clin Oncol. 2019;37:2082-8.
4. Ducrèux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goere D, et al. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v56-68.
5. Lutfi W, Zenati MS, Zureikat AH, Zeh HJ, Hogg ME. Health disparities impact expected treatment of pancreatic ductal adenocarcinoma nationally. Ann Surg Oncol. 2018;25:1860-7.
6. Huang L, Jansen L, Balavarca Y, van de Geest L, Lemmens V, Van Eycken L, et al. Nonsurgical therapies for resected and unresected pancreatic cancer in Europe and USA in 2003-2014: a large international population-based study. Int J Cancer. 2018;143:3227-39.
7. World Bank Group. Indicators: life expectancy at birth, total (years) [Internet]. Washington, DC: The World Bank Group; c2021 [cited 2021 Mar 5]. Available from: https://data.worldbank.org/indicator.
8. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: pancreatic cancer [Internet]. Bethesda, MD: U.S. National Institutes of Health, National Cancer Institute; c2020 [cited 2021 Mar 5]. Available from: https://seer.cancer.gov/statfacts/html/pancreas.html.
9. Dimou F, Sineshaw H, Parmar AD, Tamirisa NP, Jemal A, Riall TS. Trends in receipt and timing of multimodality therapy in early-stage pancreatic cancer. J Gastrointest Surg. 2016;20:93-103.
10. Hue JJ, Bingmer K, Sugumar K, Ocuin LM, Rothermel LD, Winter JM, et al. Mortality and survival among octogenarians with localized pancreatic head cancer: a national cancer database analysis. J Gastrointest Surg. 2021;25:2582-92.
11. Kang MJ, Lim J, Han SS, Park HM, Kim SW, Won YJ, et al. Impact of changes in the topographic classification of Klatskin tumor on incidence of intra- and extrapancreatic bile duct cancer: a population-based national cancer registry study. J Hepatobiliary Pancreat Sci. 2021;28:740-50.
12. National Cancer Institute. SEER training modules [Internet]. Bethesda, MD: U.S. National Institutes of Health, National Cancer Institute; 2020 [cited 2021 Mar 5]. Available from: https://training.seer.cancer.gov/.
13. Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol. 2019;10:10-27.
14. World Health Organization. World Health Organization. ICD-10: international statistical classification of diseases and related health problems. 10th revision, version for 2010. Geneva: World Health Organization; 2010.
15. Man D, Wu J, Shen Z, Zhu X. Prognosis of patients with neuroendocrine tumor: a SEER database analysis. Cancer Manag Res. 2018;10:5629-38.
16. Gordon-Dseagu VL, Devesa SS, Goggins M, Stulzenberg-Solomon R. Pancreatic cancer incidence trends: evidence from the Surveillance, Epidemiology and End Results (SEER) population-based data. Int J Epidemiol. 2018;47:427-39.
17. American College of Surgeons. Standards for oncology registry entry (STORE) 2018 [Internet]. Chicago, IL: American College of Surgeons [cited 2021 Mar 5]. Available from: https://www.facs.org/-/media/files/quality-programs/cancer/nccb_store_manual_2018.axshx.
18. Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Vol. 10. Methodological note. Bethesda, MD: National Cancer Institute; 1959.
19. World Health Organization. Barriers to early cancer diagnosis and treatment [Internet]. Copenhagen: WHO Regional Office for Europe; 2019 [cited 2021 Mar 3]. Available from: https://www.euro.who.int/en/health-topics/noncommunicable-diseases/cancer/policy/screening-and-early-detection/barriers-to-early-cancer-diagnosis-and-treatment.
20. Kasumova GG, Eskander MF, de Geus SWL, Neto MM, Tabatabaei O, Ng SC, et al. Regional variation in the treatment of pancreatic adenocarcinoma: decreasing disparities with multimodality therapy. Surgery. 2017;162:275-84.
21. Abdel-Rahman O, Xu Y, Tang PA, Lee-Ying RM, Cheung WY. A real-world, population-based study of patterns of referral, treatment, and outcomes for advanced pancreatic cancer. Cancer Med. 2018;7:6385-92.
22. Mavros MN, Coburn NG, Davis LE, Mahar AL, Liu Y, Beyfuss K, et al. Low rates of specialized cancer consultation and cancer-directed therapy for noncurable pancreatic adenocarcinoma: a population-based analysis. CMAJ. 2019;191:E574-80.
23. Shin Y, Lee L. The health insurance system in Korea and its implications. World Hosp Health Serv. 1995;31:3-9.
24. Eom BW, Jung KW, Won YJ, Kim YW. Trends and outcomes of non-compliance with treatment for gastric cancer in Korea over the 16 years from 1999 to 2015. J Gastric Cancer. 2019;19:92-101.
25. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007;246:173-80.
26. Kirkgeard J, Mortensen FV, Hansen CP, Mortensen MB, Sall M, Fristrup C. Waiting time to surgery and pancreatic cancer survival: a nationwide population-based cohort study. Eur J Surg Oncol. 2019;45:1901-5.
27. van der Geest LG, Besselink MG, van Gestel YR, Busch OR, de Hingh IH, de Jong KP, et al. Pancreatic cancer surgery in elderly patients: balancing between short-term harm and long-term benefit. A population-based study in the Netherlands. Acta Oncol. 2016;55:278-85.
28. Suzuki T, Kawai S, Ueno M, Lin Y, Kikuchi S. Treatment patterns in pancreatic cancer patients based on a hospital claims database in Japan. Jpn J Clin Oncol. 2021;51:228-34.
29. King JC, Zenati M, Steve J, Winters SB, Bartlett DL, Zureikat AH, et al. Deviations from expected treatment of pancreatic cancer in octogenarians: analysis of patient and surgeon factors. Ann Surg Oncol. 2016;23:4149-55.
30. Marosi C, Koller M. Challenge of cancer in the elderly. ESMO Open. 2016;1:e000020.